The current patent provided an intermediate compound in synthesizing PPAR modulating compounds like thiazolidinedione in the treatment or prevention of metabolic disorders such as obesity, hypertension, inflammatory diseases, and diabetes. Here, PPARA is linked to metabolic disease.